Document Detail


GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.
MedLine Citation:
PMID:  21206329     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: GLUT-1 has been found to have an important role in the upregulation of various cellular pathways and implicated in neoplastic transformation correlating with biological behavior in malignancies. However, literature regarding the significance of GLUT-1 expression in pancreatic neoplasia has been limited and controversial.
METHODS: Immunohistochemical expression of GLUT-1 was tested in a variety of pancreatic neoplasia including ductal adenocarcinomas (DAs), pancreatic intraepithelial neoplasms (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and serous cystadenomas.
RESULTS: There was a progressive increase in the expression of GLUT-1 from low- to higher-grade dysplastic lesions: All higher-grade PanINs/IPMNs (the ones with moderate/high-grade dysplasia) revealed noticeable GLUT-1 expression. Among the 94 DAs analyzed, there were minimal/moderate expression in 46 and significant expression in 24 DAs. However, all 4 clear-cell variants of DAs revealed significant GLUT-1 immunolabeling, as did areas of clear-cell change seen in other DAs. Moreover, all 12 serous cystadenomas expressed significant GLUT-1. GLUT-1 expression was also directly correlated with DA histological grade (P = 0.016) and tumor size (P = 0.03).
CONCLUSIONS: GLUT-1 may give rise to the distinctive clear-cell appearance of these tumors by inducing the accumulation of glycogen in the cytoplasm. Additionally, because GLUT-1 expression was related to histological grade and tumor size of DA, further studies are warranted to investigate the association of GLUT-1 with prognosis and tumor progression.
Authors:
Olca Basturk; Rajendra Singh; Ecmel Kaygusuz; Serdar Balci; Nevra Dursun; Nil Culhaci; N Volkan Adsay
Related Documents :
23111059 - Photon activated therapy (pat) using monochromatic synchrotron x-rays and iron oxide na...
24152759 - Tumor hypoxia as a driving force in genetic instability.
8457709 - In vitro evaluation of the antineoplastic activity of combretastatin a-4, a natural pro...
18477509 - Synthesis and antitumor activity of benzils related to combretastatin a-4.
11858989 - New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbo...
14698199 - Synthesis and biological activity of new quinoxaline antibiotics of echinomycin analogues.
19116809 - A biopsychosocial perspective on adjustment and quality of life following brain tumor: ...
25114039 - Caspase-2 regulates oncogene-induced senescence.
23338489 - Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressi...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pancreas     Volume:  40     ISSN:  1536-4828     ISO Abbreviation:  Pancreas     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-11     Completed Date:  2011-08-17     Revised Date:  2014-01-01    
Medline Journal Info:
Nlm Unique ID:  8608542     Medline TA:  Pancreas     Country:  United States    
Other Details:
Languages:  eng     Pagination:  187-92     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carcinoma in Situ / chemistry
Carcinoma, Pancreatic Ductal / chemistry
Carcinoma, Papillary / chemistry
Chi-Square Distribution
Cystadenoma, Serous / chemistry
Glucose Transporter Type 1 / analysis*
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Neoplasm Invasiveness
Neoplasm Staging
Neoplasms, Cystic, Mucinous, and Serous / chemistry
Pancreatic Neoplasms / chemistry*,  diagnosis,  mortality,  pathology,  therapy
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Risk Assessment
Risk Factors
Tumor Markers, Biological / analysis*
Turkey
United States
Up-Regulation
Grant Support
ID/Acronym/Agency:
CA101936/CA/NCI NIH HHS; P20 CA101936/CA/NCI NIH HHS; P20 CA101936-05/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Glucose Transporter Type 1; 0/SLC2A1 protein, human; 0/Tumor Markers, Biological
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genistein Reduces Hyperglycemia and Islet Cell Loss in a High-Dosage Manner in Rats With Alloxan-Ind...
Next Document:  Prospective Comparison of Endoscopic Ultrasonography and Magnetic Resonance Cholangiopancreatography...